Alfa-TIL^TM Platform

Online Inquiry

* Your Name

* E-mail Address

Phone Number

Services Interested

Project Description

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and therapeutic services for individuals.

Multi-Omics TIL Profiling

Understanding the composition and functionality of tumor-infiltrating lymphocytes (TILs) is key to advancing TIL-based therapies. Beyond basic phenotyping, multi-omics profiling enables in-depth characterization of cellular states, clonality, and molecular signatures that drive antitumor activity or resistance. Alfa-TIL^TM provides comprehensive multi-omics TIL profiling services to support translational research and product optimization.

Introduction to Multi-Omics Profiling in TIL Therapy

TILs are inherently heterogeneous, comprising diverse subsets of effector, memory, and exhausted T cells. Conventional surface marker analysis may not fully capture their therapeutic potential or biological complexity. Multi-omics approaches—including transcriptomic, immune repertoire, and high-dimensional protein profiling—provide a deeper understanding of:

TIL functional states (activation, exhaustion, memory differentiation)
Clonal expansion and diversity of tumor-reactive TCRs
Response-associated gene expression programs
Comparative signatures across engineered and unmodified populations

Fig.1 Overflow of the omics integration for precision medicine. (Raufaste-Cazavieille V, et al., 2022)

Importance of Multi-Omics Profiling

Unlocking Functional Complexity

Conventional surface marker analysis cannot discern therapeutically critical TIL subsets—such as stem-like progenitors versus terminally exhausted cells—that coexist within tumors. Multi-omics integrates transcriptional states, epigenetic programming, and protein expression to reveal functional hierarchies governing TIL persistence and reinvigoration potential, essential for predicting therapy responsiveness.

Validating Tumor-Reactive Clonality

Fewer than 5% of TIL clones recognize tumor antigens, yet bulk profiling obscures these rare populations. Correlating TCR clonality (TCR-seq) with tumor-specific gene signatures (e.g., cytotoxicity/activation markers) through multi-omics analysis definitively identifies target-reactive clones, preventing misdirected therapeutic development.

Deconvoluting Resistance Networks

Therapy failure often stems from layered immunosuppressive mechanisms in the TME—metabolic constraints, epigenetic silencing, and stromal crosstalk. Integrated spatial and molecular profiling exposes these adaptive resistance pathways, enabling rational combination strategies to overcome TIL dysfunction.

Our Services

Alfa-TIL^TM delivers multi-modal analytical services tailored to preclinical TIL samples. Profiling can be performed on fresh or cryopreserved TIL products, either as standalone assays or part of an integrated workflow.

Workflow of Multi-Omics TIL Profiling

Each stage of the Alfa-TIL™ platform is offered as a standalone or integrated service.

Sample Preparation

Fresh or cryopreserved TIL products are processed for nucleic acid extraction and/or staining. A small aliquot may be set aside for complementary assays.

Data Generation

Transcriptomic, single-cell omics, and TCR sequencing are performed in parallel using validated protocols to generate high-quality multi-omic data from the same TIL sample.

Integration & Analysis

Results from each assay are normalized and integrated. Computational pipelines identify gene-expression modules, clonotype expansions and phenotypic clusters.

Alfa-TIL^TM supports TIL-focused discovery with integrated, high-resolution profiling technologies. Whether validating engineered TILs, comparing treatment conditions, or identifying biomarkers of potency, our multi-omics platform provides the depth and flexibility your program demands. Contact us to learn how our TIL profiling services can support your next stage of development.

Reference

Raufaste-Cazavieille, et al. Multi-omics analysis: Paving the path toward achieving precision medicine in cancer treatment and immuno-oncology. Frontiers in Molecular Biosciences. 2022. (9) 962743.

For research use only.